about
Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancerThe treatment of climacteric symptomsMenopausal symptoms in young survivors of breast cancer: a growing problem without an ideal solutionAssociation Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in miceConjugated estrogens for the treatment of menopausal symptoms: a review of safety data.Effects of total flavonoids from Drynariae Rhizoma prevent bone loss in vivo and in vitro.Stem cells in aged mammalian ovariesQuantitative detection of 4-hydroxyequilenin-DNA adducts in mammalian cells using an immunoassay with a novel monoclonal antibody.Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer.The 2012 hormone therapy position statement of: The North American Menopause Society.Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States.17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo.Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer.Ovarian cancer: diagnosis and treatmentMenopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy.The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.Oral contraceptives decrease the prevalence of ovarian cancer in the henCommon variation in Nemo-like kinase is associated with risk of ovarian cancer.Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control studyMenopausal hormone therapy and ovarian cancerOvarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variablesRecent progress in the diagnosis and treatment of ovarian cancerA sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010.Endometriosis-associated ovarian cancer: a review of pathogenesisInhibition of the long non-coding RNA MALAT1 suppresses tumorigenicity and induces apoptosis in the human ovarian cancer SKOV3 cell line.BRCA and Early Events in the Development of Serous Ovarian Cancer.Investigation of mammographic breast density as a risk factor for ovarian cancer.Epidemiology of ovarian cancer: a review.Metabonomic analysis reveals efficient ameliorating effects of acupoint stimulations on the menopause-caused alterations in mammalian metabolism.Peri- and post-menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy: new insights and clinical management.HRT in difficult circumstances: are there any absolute contraindications?Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.Safety of hormone replacement therapy in gynaecological cancer survivors.Ovarian epithelial tumors and reproductive factors: a systematic review.Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health.Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix.
P2860
Q24307419-1EB5F755-2F4D-4F32-9121-24422046FCFCQ26992273-C3D45024-5795-4D76-A814-2B988CED1C1BQ27025094-4C0002C8-B540-4B54-92EF-B6A743464672Q30277016-3D1EA865-2950-48EB-B5DC-DE8571A236C3Q30414345-85BEB05E-AAA7-4F29-BFB4-A5A929AF3C76Q30659580-C166B4DC-B8C0-41FD-A50B-57FAD115F8A2Q33716948-9305DCD5-108F-4CF6-8899-237BAECA180CQ33722175-2D95FECA-A438-4791-B8CF-72A83744D4BDQ33959481-5DA96B94-E6DE-4B2F-801E-721ACE048566Q34099786-4F3B148A-FF26-4DD2-B325-C2A1D923E07FQ34161400-1CBD178C-958B-4254-B61C-476823AE6BF5Q34177267-41682A63-447F-4C3B-B470-06EAB2D7748BQ34343315-5EC1A250-E754-45A6-A247-75428628AC44Q34531044-A978AE53-4ACE-4270-B797-0115D8756723Q34807665-2C8F6EE2-C75E-4446-9369-30440D1378E3Q35407356-53B01578-B0BB-4571-9AAA-E66DC508B17DQ35594488-EB218E10-3E99-472D-89B1-BADB29003C63Q35600183-06A6E7CA-5EEC-41E6-84E8-703F74A9C32AQ35646553-C6221273-D02B-46FC-9D9D-CC67E9BE0713Q35740147-238F37FC-6C4A-4207-8A21-52DBF7199D9EQ35815383-75E69434-2F78-4134-97EB-4064F266F1A9Q36088013-73E67439-91B8-46E0-A143-BB647EAD926AQ36159386-73B1F1EA-5E28-4BCC-98D4-F25317132E46Q36288027-DF942744-0AFA-4350-9EFA-94E2A5C87A88Q36523707-D3F1B2F2-3F0A-432E-A395-3A11671D3897Q36622857-FA097000-F812-4EAA-9F99-75F1E539DA95Q36713568-EFE49DFB-9DC6-4DC6-817F-EF666B11529EQ36790454-D614089D-13A5-41F1-B082-6C4B8DBC8F42Q36954048-EA67D9E1-C532-4AEF-A31D-6C05BDCE72FDQ37513137-595BEA1A-5DE0-483C-A885-08AAC033DBCAQ37532651-44C505F7-5E60-45C7-B537-1411E059B42AQ37720438-3EEF03D4-529B-4C8B-B3A7-A63F6E7862C7Q37735393-2C8147AF-CCA5-4892-9980-CA222CE10590Q37760524-9A40715B-341E-4693-8D18-F1760E14EA44Q37847568-92763ABE-1C6C-4949-BD7D-0EEA558D2680Q37989179-5F195300-5221-4F6A-A50A-D9C4B6580C90Q38004049-FCA7AC80-7608-43CA-B371-E42BA1BA3DB0Q38090489-F99B14BA-D03E-4397-9117-5446547FFD66Q38106748-F084A27F-9F3A-4FA2-818D-D35B8C04C89BQ38437108-E7093E0B-99E8-4E0A-B641-A17D2B9CFAE4
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Hormone therapy and ovarian cancer.
@en
Hormone therapy and ovarian cancer.
@nl
type
label
Hormone therapy and ovarian cancer.
@en
Hormone therapy and ovarian cancer.
@nl
prefLabel
Hormone therapy and ovarian cancer.
@en
Hormone therapy and ovarian cancer.
@nl
P2093
P356
P1476
Hormone therapy and ovarian cancer.
@en
P2093
Lina Steinrud Mørch
Ojvind Lidegaard
Susanne Krüger-Kjaer
P304
P356
10.1001/JAMA.2009.1052
P407
P577
2009-07-01T00:00:00Z